SRR661179
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.312
- HEDGEHOG_SIGNALING+0.282
- SPERMATOGENESIS+0.205
- KRAS_SIGNALING_DN+0.074
- MYOGENESIS+0.066
- APICAL_JUNCTION-0.007
- PROTEIN_SECRETION-0.039
- APICAL_SURFACE-0.075
- ESTROGEN_RESPONSE_LATE-0.078
- PEROXISOME-0.087
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.514
- MYC_TARGETS_V1-0.469
- TGF_BETA_SIGNALING-0.439
- OXIDATIVE_PHOSPHORYLATION-0.411
- G2M_CHECKPOINT-0.410
- IL6_JAK_STAT3_SIGNALING-0.399
- MYC_TARGETS_V2-0.392
- DNA_REPAIR-0.391
- E2F_TARGETS-0.387
- UNFOLDED_PROTEIN_RESPONSE-0.383
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1334717 | GTEX | — | 0.967 |
| 2 | SRR1325986 | GTEX | — | 0.938 |
| 3 | SRR1478032 | GTEX | — | 0.937 |
| 4 | MNG700 | — | — | 0.936 |
| 5 | SRR1443713 | GTEX | — | 0.932 |
| 6 | BS_3P20Q2C3 | low-grade glioma | — | 0.926 |
| 7 | SRR1357021 | GTEX | — | 0.925 |
| 8 | MNG1280 | — | — | 0.924 |
| 9 | BS_90B22NGP | ATRT | — | 0.924 |
| 10 | MNG226 | — | — | 0.923 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 5 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.312 | Cobimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.282 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.205 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.074 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.066 | Inavolisib | — uncovered |